On 3 February 2023, it received approval for patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who had previously received endocrine-based therapy and at least two additional systemic treatments in the metastatic setting. This evidence concerns the gene ERBB2 and breast cancer.